43 results about "Immune receptor" patented technology

The present invention relates generally to a plant cell-surface immune receptor engineered to modulate an immune response in a plant, cell or seed, as well as nucleic acid molecules encoding the engineered receptor, and methods of use. In particular, the present invention relates to a plant cell-surface immune receptor into which a coiled-coil (CC) motif is integrated to enhance or modify the plant's immune response, with utility in reducing pathogen infection and improving pathogen resistance.

The present invention provides for an engineered, genetically modified, and / or synthetic plant receptor comprising a binding sequence that is capable of binding a fungal pathogen Avr ligand; wherein the non-engineered, genetically unmodified, and / or naturally occurring plant receptor does not bind the fungal pathogen Avr ligand, or bind with a lower binding affinity.

Methods are provided for predicting a subject's infection status using high-throughput T cell receptor sequencing to match the subject's TCR repertoire to a known set of disease-associated T cell receptor sequences. The methods of the present invention may be used to predict the status of several infectious agents in a single sample from a subject. Methods are also provided for predicting a subject's HLA status using high-throughput immune receptor sequencing.

Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen / immune receptor interactions, in a single-cell format.

Disclosed are methods for determining the immunological status of the adaptive immune system of a subject by identifying and quantifying rearranged DNA (and / or subsequently transcribed RNA) sequences encoding T cell receptor (TCR) and / or immunoglobulin (IG) polypeptides, in a lymphoid DNA-containing sample from the subject. TCR and / or IG sequence diversity and sequence distribution permit immunocompetence and immune repertoire assessment and reflect the degree of T cell or B cell clonality and clonal expansion in the sample. Methods for stratifying patient populations on the basis of immunocompetence including likelihood of responding to immunotherapy are also described.

The invention relates to the technical field of medical engineering, in particular to an NK cell delivery data processing method and system based on magnetic targeting. The method comprises the following steps: inquiring an immune receptor protein structure of natural killer cells; injecting a sodium chloride solution, adding an immune receptor protein structure, and reacting to generate an aptamer structure; the method comprises the following steps: combining streptavidin in a pre-prepared glycosyl magnetic microsphere to obtain a high-affinity magnetic bead; carrying out molecular docking on the high-affinity magnetic beads and the aptamer structure, recording a docking score, and generating an optimized aptamer; recording the magnetic bead mass ratio of the optimized aptamer; capturing the natural killer cells by adopting the optimized aptamer, and shooting to obtain a fluorescent microscopic image; and recording the dyeing condition of the fluorescent microscopic image, determining the survival state of the NK cells, marking the position information of the living cells, and generating an NK cell delivery efficiency table by using the mass ratio of the magnetic beads. Based on a medical engineering technology, the homing rate and the delivery efficiency of the NK cells at the liver injury part are improved.

Disclosed herein is a method for enhancing adoptively transferred autologous or allogeneic immune effector T-cells (including gamma delta T cells (γδ-T cells)) by targeting the thioredoxin (TRX)-interacting protein (TXNIP). In addition, disclosed herein are cDNA sequences for the co-expression of immune receptors (CARs, TCRs, etc) in combination with guide RNAs, and / or artificial or natural microRNAs, and / or shRNAs targeting TXNIP.

Described herein are techniques for predicting whether a subject will experience an immune-related adverse event (irAE) in response to administration of an immune checkpoint inhibitor (ICI) therapy. In some embodiments, the techniques include: determining a likelihood that the subject will experience the irAE in response to administration of the ICI therapy, the determining comprising: performing: (a) processing clinical data using a first machine learning (ML) model to output a first likelihood that the subject will experience the irAE, (b) processing RNA sequencing data using a second ML model to output a second likelihood that the subject will experience the irAE, and / or (c) processing immune receptor data using a third ML model to output a third likelihood that the subject will experience the irAE; and processing the first, second, and / or third likelihoods using a fourth ML model trained to predict the likelihood that the subject will experience the irAE.

Disclosed is a Butyrophilin Subfamily 2 Member A1 (BTN2A1) binding peptide with an amino acid sequence comprising an amino acid other than glutamic acid, for example, tryptophan, at a position corresponding to position 22 shown in SEQ ID NO: 1; an amino acid other than arginine, for example, tyrosine, at a position corresponding to position 73 shown in SEQ ID NO: 1; and / or an amino acid other than threonine, for example, histidine or tryptophan, at a position corresponding to position 81 shown in SEQ ID NO: 1. The BTN2A1 binding peptide may be comprised in an (exogeneous) immune receptor or extracellular domain thereof, preferably a γδ T-cell receptor or extracellular domain thereof, more preferably a γ9δ2 T-cell receptor or extracellular domain thereof. This disclosure particularly relates to use in therapy, preferably for use in treatment of a cancer and / or an infection, or for use in diagnostic methods.

Provided herein are compositions and methods for increasing the amount aryl-lactates in fermented foods. The methods can comprise delivering alpha-ketoglutarate (AKG), trisodium citrate dehydrate (CIT), or both AKG and CIT; and / or phenylpyruvic acid (PPyA), 4-hydroxyphenylpyruvic acid (4HPPyA), indole-3-pyruvic acid (IPyA) or combinations thereof; and / or phenylalanine (Phe), tyrosine (Tyr), and / or tryptophan or combinations thereof to fermented foods and fermented food matrices. Optionally, bacteria with aromatic amino transferase (ArAT) and / or phenyllactate dehydrogenase activity can also be added to the fermented foods and fermented food matrices. Also provided are methods to increase the bioactivity of fermented foods towards an immune receptor (aryl hydrocarbon receptor—AhR). Also provided are methods to more effectively maintain food matrix AhR bioactivity across food storage times of up to 4 weeks. Also provided are methods of inducing weight loss, reducing fat mass, and / or reducing glucose intolerance in mammals.

The invention belongs to the technical field of biology, and particularly discloses a TCR / BCR space transcriptome sequencing method. The method is characterized in that a unique space transcriptome chip is adopted, and a capture probe of the chip sequentially comprises a universal sequence 1, a space address code, a unique molecular tag, a universal sequence 2 and a Poly dT sequence; after a cDNA library is constructed by using the chip, cyclizing the cDNA library, so that a spatial address code is physically adjacent to a variable region; and then taking the cyclized DNA as a template, and carrying out multiple PCR amplification by using a primer complementary with the universal sequence 2 and a specific primer aiming at the constant region, so as to enrich a fragment simultaneously containing a complete variable region sequence and a space address code. Through cooperation of chip design and cyclization enrichment, a variable region primer pool is not needed, and the space variable region sequence of the immune receptor can be captured in an unbiased and efficient manner.

Single domain antibodies which specifically bind to mesothelin and mesothelin binding proteins, anti-mesothelin anti-bodies and antibody fragments thereof, antibody drug conjugates, synthetic immune receptors, and diagnostic agents comprising the same are disclosed. Also disclosed are pharmaceutical compositions comprising any of the foregoing and uses of any of the foregoing in the treatment and / or diagnosis and / or monitoring of a disease associated with mesothelin expression.

Provided herein are engineered immune effector cells that include an engineered immune receptor, wherein the engineered immune receptor comprises an antigen binding domain that binds specifically to an immunoglobulin variable heavy chain (IGHV) gene-encoded protein sequence present on a surface of a B cell.

The invention discloses a plant immune receptor LC-BAK1 and application thereof in plant epidemic disease resistance, and belongs to the technical field of plant disease control. The invention discovers and solves the technical obstacle of constitutive cell death caused by direct fusion of LC and BAK1 for the first time. By introducing regulation and control structural domains such as TM3, the receptor is started only when pathogenic bacteria exist, and the application safety is extremely high. The TM3-LC-BAK1 receptor is specifically activated by the PsAvh85 to trigger a potent immune response including defensive gene up-regulation and active oxygen outbreak, so that the invasion of phytophthora sojae can be effectively resisted.

The present disclosure provides high-performance immune-activation reporter cell line set. A set of nucleic acid constructs comprising one or more response elements operatively linked to a TATA box motif promoter or a minimal IL-2 promoter are provided. A set of reporter cell lines comprising a polynucleotide sequence encoding a reporter protein under the control of one or more response elements operatively linked to a TATA box motif promoter or a minimal IL-2 promoter is also provided. The provided set of reporter cells enable sensitive and signal-enhanced bioassay performance to reflect and evaluate adaptive immune cell activation / inhibition regulated by the immune receptors CD3, co-stimulatory CD28 and related signaling pathways, and avoid responding bias triggered by particular transcription factor. A controllable engineer method for a functional cell line is further provided.

Agents that are less than 100 kilodaltons, bind a membranal immune receptor on a surface of a cell and inhibit proteolytic cleavage of the immune receptor are provided. Methods of treating cancer and improving immunotherapy comprising administering the agents are also provided.

Provided herein are compositions, systems, and methods suitable for in vivo delivery of CAR-encoding expression constructs. Expression constructs engineered to express a heterologous immune receptor under control of an immune cell-specific promoter are described (for example, to express a CAR under control of a T cell-specific promoter). The expression constructs can be used in combination with a lipid-based delivery vector (LDV) delivery system that facilitates effective delivery and repeat dosing.

The invention discloses a chimeric immune receptor and application of the chimeric immune receptor to improvement of phytophthora resistance of plants, and belongs to the technical field of plant disease control. The chimeric immune receptor disclosed by the invention can specifically recognize the phytophthora sojae effector Avh85 or a homolog thereof, and can be activated only when a specific pathogenic bacterium effector exists, so that accurate recognition of target pathogenic bacteria is realized, and unnecessary energy consumption of a plant immune system is avoided. Once the chimeric immune receptor disclosed by the invention is activated, multiple and potent immunoreactions including significant up-regulation of defensive genes, active oxygen outbreak and MAPK phosphorylation can be initiated, a firm defensive barrier is formed together, and expansion of pathogenic bacteria can be rapidly and efficiently suppressed.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

This invention relates to multispecific antibodies comprising a first Fv fragment targeting CD3, a second Fv fragment targeting an immune receptor such as CD137 or PD-L1, and one or more binding moieties targeting tumor-associated antigens. The therapeutic use of these multispecific antibodies in cancer therapy is also provided herein.

The present invention relates to a butyrophilin subfamily 2 member A1 (BTN2A1)-binding peptide having an amino acid sequence comprising an amino acid other than glutamic acid, such as tryptophan, at the position corresponding to position 22 of SEQ ID NO: 1, an amino acid other than arginine, such as tyrosine, at the position corresponding to position 73 of SEQ ID NO: 1, and / or an amino acid other than threonine, such as histidine or tryptophan, at the position corresponding to position 81 of SEQ ID NO: 1. The BTN2A1-binding peptide may be contained in an (exogenous) immune receptor or its extracellular domain, preferably a γδ T cell receptor or its extracellular domain, more preferably a γ9δ2 T cell receptor or its extracellular domain. The present invention particularly relates to use in therapy, preferably in the treatment of cancer and / or infection, or in diagnostic methods.

The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of FSHR. The invention provides novel peptides that specifically bind to Follicle-stimulation hormone receptor (FSHR).

The present invention provides a new therapeutic approach for the treatment of diseases, such as auto- inflammatory and tumor diseases. It makes use of recombinant T cells expressing engineered chimeric antigen receptors (CARs), artificial immune receptors (AIRs) or recombinant TCRs and an engineered synthetic, transmembrane protein comprising the binding domain of a TNFR ligand. The transmembrane protein comprising the binding domain of a TNFR ligand is engineered in a manner which allows the TNFR ligand to bind to its receptor on the same T cell, thereby stimulating its own survival via Nfkb activation and other pro-survival signaling pathways.

The invention provides an automatic screening and optimizing method and system for bispecific immune receptors, and belongs to the field of immunotherapy. The method comprises the following steps: acquiring a to-be-screened bispecific immune receptor sequence, a first target antigen sequence and a second target antigen sequence, and presetting a mutation domain of a bispecific immune receptor; performing parallel conformation prediction on the bispecific immune receptor sequence and the two target antigens based on the structure prediction model, and screening out an optimal conformation based on confidence; generating candidate objects carrying different mutation combinations through a sequence generation model based on the mutation domain of the bispecific immune receptor in the optimal conformation; constructing a multi-target scoring function, and carrying out at least two rounds of screening on the candidate objects: screening a first candidate set according to stability and interface indexes in the first round, and carrying out parallel docking simulation calculation on the first candidate set and the two target antigens in the second round to calculate docking energy and interface residue annotations, and updating the scoring function based on a calculation result to obtain an optimized bispecific immune receptor, thereby realizing automatic screening and optimization of the bispecific immune receptor.

The embodiment of the application provides a kind of antigen specificity determination method, device, equipment and storage medium, at least be applied to artificial intelligence field, medical field and adaptive immune receptor, wherein, method includes: double-chain biological information of cell receptor is carried out word encoding processing, obtains amino acid word sequence;Wherein, at least one amino acid word in the amino acid word sequence is indicated;Using pre-trained amino acid sequence prediction model, based on the amino acid word sequence, the cell receptor is extracted, and the amino acid sequence representation of the cell receptor is obtained;Wherein, the amino acid sequence prediction model is obtained by training the data obtained by shielding processing part of sample amino acid word representation in sample data;Based on the amino acid sequence representation, the antigen specificity of the cell receptor is determined;Through the application, the cell receptor can be accurately extracted, so that the antigen specificity of the cell receptor is accurately determined.

The invention discloses a high-throughput gene sequencing data analysis system based on deep learning, and particularly relates to the technical field of bioinformatics, the system firstly performs quality control and unified coordinate mapping on multi-source sequencing reads, and constructs unified tensor representation; fusing external information through a deep feature extraction network to generate a comprehensive feature vector, and calculating a variation comprehensive risk index by using a gradient boosting tree model; then longitudinal variation risk and immune receptor rearrangement sequencing data are integrated, a clone phylogenetic structure is reconstructed, the internal growth rate, the competition coefficient and the immune clearance intensity coefficient of each clone are estimated, and a clone abundance time sequence with consistent time and space is obtained; and finally, constructing a clone evolution feature vector, mapping the clone evolution feature vector into an immune escape risk index through a support vector machine model, realizing sorting and grading of high-risk clone, and retaining a complete chain capable of being traced back to underlying evidence in the whole process.

Aspects of the technology disclosed herein relate to methods of preparing and analyzing nucleic acids, e.g., cfDNA, and nucleic acids encoding immune receptors and immunoglobulins. In some embodiments, methods for preparing nucleic acids for sequence analysis (e.g., using next-generation sequencing) are provided herein.

The invention is directed to a method for determining the sequence of immune receptors expressed in target cells provided from a sample comprising target and non-target cells suspended in a fluid, especially TCR and BCR receptors. The assay has advantages over conventional RNA isolation-based approach. Cells are magnetically enriched on the column, and then RT reaction is carried out without eluting the cells, using the column as a reaction tube. Quantification of TCR libraries is produced with the standard workflow (with RNA isolation), and with on-column cDNA synthesis approach.

The disclosure provides compositions and method that promote adoptive cellular therapy. The disclosure provides polynucleotides, vectors, systems and cells comprising chimeric antigen receptors (CARs), synthetic immune receptors (SIRs), and the like in combination the specific activators of NFkB activity, thus improving cellular proliferation, expression and reduced apoptosis, which improves cell persistence in adoptive cell therapy.

The application relates to a KASP molecular marker of an NbEDS1 gene, a detection method and application, and belongs to the technical field of plant molecular breeding. The KASP molecular marker is designed according to a specific 97 bp InDel site in a Nicotiana benthamiana NbEDS1 gene mutant, the wild-type allele is C (containing a 97 bp insertion sequence), the mutant allele is A (the insertion sequence is deleted), the marker has the advantages of high specificity, fast detection speed, low cost, high throughput and high accuracy, and can be applied to genotype identification of the NbEDS1 gene mutant of the Nicotiana benthamiana, rapid screening of mutant materials in related research on a TNL type immune receptor disease resistance pathway, and genetic analysis and breeding selection related to the NbEDS1 gene.